诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

已收盘 01-12 16:08:30

13.260

-0.220

-1.63%

最高13.740	最低13.150	成交量532.60万
今开13.470	昨收13.480	日振幅4.38%
总市值233.64亿	流通市值198.10亿	总股本17.62亿
成交额7,067万	换手率0.36%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.26,"timestamp":1768205310006,"preClose":13.48,"halted":0,"volume":5326000,"delay":0,"floatShares":1494000000,"shares":1762000000,"eps":-0.29085879573681794,"marketStatus":"已收盘","change":-0.22,"latestTime":"01-12 16:08:30","open":13.47,"high":13.74,"low":13.15,"amount":70672515,"amplitude":0.043769,"askPrice":13.26,"askSize":7000,"bidPrice":13.24,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.15940851906659081,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.48,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.663082,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.58,"timestamp":1768201200000,"preClose":22.57,"halted":0,"volume":9473700,"delay":0,"premium":"-47.51"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2602553569","title":"每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553569?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070417,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，诺诚健华报收于22.57元，较上周的20.52元上涨9.99%。本周，诺诚健华1月9日盘中最高价报22.85元。本周关注点公司公告汇总：截至2025年12月31日，诺诚健华总股本未变，已发行股份无增减。公司公告汇总：2023年及2024年人民币股激励计划合计剩余可授出14,176,450股。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2602373081","title":"医药生物行业炎症性肠病：市场空间大 研发路径愈发清晰 中国创新药公司有望深度参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373081","media":"天风证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602373081?lang=zh_cn&edition=full","pubTime":"2026-01-09 00:00","pubTimestamp":1767888000,"startTime":"0","endTime":"0","summary":"2024 年IBD 患者数量接近91 万人，并预计2025 年患者数将达150 万，由少见病走向常见病。根据Abivax估算，2024 年至2030 年IBD 药物市场有望从237 亿美元增至308 亿美元，其中UC 增速更快。中国创新药公司有望深度参与IBD 大赛道在前沿靶点上，中国药企在TL1A 方向储备较多，有超20 款药物在研，覆盖单抗与双抗等形态。此外，辰欣药业的WXSH0176 已开展UC 的临床试验，未来可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109152515a4af33a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109152515a4af33a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","09969","BK1161"],"gpt_icon":0},{"id":"2601806825","title":"诺诚健华：公司营业收入2025年前三季度实现加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806825","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601806825?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:36","pubTimestamp":1767792974,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，诺诚健华在互动平台回答投资者提问时表示，公司营业收入2025年前三季度实现加速增长，公司对全年业绩目标的达成充满信心，全年业绩请关注公司按期披露的业绩预告及定期报告。二级市场股价受多种因素影响，请您注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611756388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"gpt_icon":0},{"id":"2601353604","title":"每日卖空追踪 | 诺诚健华 01月07日卖空量成交29.1万股，卖空比例为2.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601353604","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601353604?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774644,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间01月07日，涨3.41%，卖空量成交29.1万股，较上一交易日减少71.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163640a6fde148&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163640a6fde148&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2601139718","title":"诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601139718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601139718?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:20","pubTimestamp":1767709235,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，诺诚健华报收于20.92元，较前一交易日下跌2.65%，最新总市值为369.16亿元。公司近日发布公告，披露截至2025年12月31日的证券变动月报表。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。公司存在两项股权激励计划：2023年人民币股激励计划剩余可授出4,531,250股，2024年人民币股激励计划剩余可授出9,645,200股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09969","BK0239","BK1161","688428","BK1574"],"gpt_icon":0},{"id":"2601001578","title":"每日卖空追踪 | 诺诚健华 01月05日卖空量成交50.6万股，卖空比例为5.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601001578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601001578?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601842,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间01月05日，涨4%，卖空量成交50.6万股，较上一交易日增加90.23%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163845a49e2d09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163845a49e2d09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2601681001","title":"诺诚健华01月05日主力净流入297.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2601681001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601681001?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:15","pubTimestamp":1767600933,"startTime":"0","endTime":"0","summary":"01月05日, 诺诚健华股价涨4.00%，报收13.00元，成交金额1.3亿元，换手率0.66%，振幅8.32%，量比1.47。诺诚健华今日主力资金净流入297.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.37%，主力资金累计净流入1349.1万元；近20日主力资金累计净流入2219.2万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161825a49e1476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105161825a49e1476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2600040683","title":"新药周观点：2025年约101款创新药国内获批上市 行业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2600040683","media":"国投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600040683?lang=zh_cn&edition=full","pubTime":"2026-01-04 00:00","pubTimestamp":1767456000,"startTime":"0","endTime":"0","summary":"本周新药行业重点分析：2025 年我国创新药行业蓬勃发展，根据NMPA 与药渡数据，2025 年NMPA 共批准了约101 款创新药，这一数量再创近年来获批新药数量的新高；其中2025 年共批准上市国产创新药（含引进）63 款， 进口创新药38 款，国内创新药行业蓬勃发展。本周新药临床申请获批准&受理情况：本周国内有18 个新药的临床申请获批准，有52 个新药的临床申请获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104174118a6f16fa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","06978","BK1574","BK1161","HK0000165453.HKD","09969"],"gpt_icon":0},{"id":"2600037932","title":"诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037932","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600037932?lang=zh_cn&edition=full","pubTime":"2026-01-02 09:22","pubTimestamp":1767316966,"startTime":"0","endTime":"0","summary":"【诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组】诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601023607534023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK0239","III","BK1161","BK1574","688428","BK4134"],"gpt_icon":0},{"id":"2600039998","title":"每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039998?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:05","pubTimestamp":1767297912,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，诺诚健华报收于21.44元，较上周的22.2元下跌3.42%。本周，诺诚健华12月23日盘中最高价报22.67元。诺诚健华当前最新总市值362.1亿元，在化学制药板块市值排名12/150，在两市A股市值排名527/5181。本周关注点公司公告汇总：诺诚健华根据2023年股权激励计划授出合计1,400,000份受限制股份单位。公司公告汇总诺诚健华医药有限公司于2025年12月31日根据2023年股权激励计划授予两名雇员参与者合计1,400,000份受限制股份单位，约占公司已发行股份总数的0.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2595705107","title":"打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片","url":"https://stock-news.laohu8.com/highlight/detail?id=2595705107","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595705107?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:59","pubTimestamp":1767193140,"startTime":"0","endTime":"0","summary":"\n                                                诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年...                                                [全文]\n","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767193147129723.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767193147129723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["159992","BK1574","09969","06978","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2595727116","title":"诺诚健华(09969)授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727116?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2025年12月31日，公司根据2023年股权激励计划授予两名承授人140万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","09969","688428","BK1574"],"gpt_icon":0},{"id":"2595578038","title":"每日卖空追踪 | 诺诚健华 12月29日卖空量成交12.3万股，卖空比例为1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595578038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595578038?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:30","pubTimestamp":1766997041,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月29日，跌3.28%，卖空量成交12.3万股，较上一交易日减少27.65%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163631a6dc4c10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229163631a6dc4c10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2594183772","title":"诺诚健华[14C]ICP - 488启动Ⅰ期临床 适应症为银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=2594183772","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594183772?lang=zh_cn&edition=full","pubTime":"2025-12-26 18:31","pubTimestamp":1766745060,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，北京诺诚健华医药科技有限公司的[14C]ICP - 488在中国健康成年男性受试者中的物质平衡和生物转化研究的Ⅰ期临床试验已启动。本次试验主要目的为定量分析健康受试者单次口服[14C]ICP - 488后排泄物中的总放射性、全血和血浆中的总放射性等；获得血浆、尿液和粪便中的代谢物谱，确定代谢和消除途径。次要目的为获得血浆中ICP - 488及其代谢产物的PK特征，评估安全性。[14C]ICP - 488为化学药物，适应症为银屑病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226183318a47b5475&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226183318a47b5475&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2593342479","title":"国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593342479","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593342479?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:58","pubTimestamp":1766559522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，预计诺诚健华2025-27年收入分别为人民币20.1亿、20.6亿、25.6亿元，净利润分别为人民币1.17亿、0.17亿、1.88亿元，公司持有现金及等价物约72亿元，现金足够进行创新研究。根据DCF模型，给予目标价16.81港元，给予买入评级，较现价有28%的升幅。CDE已批准启动奥布替尼治疗SLE的III期临床试验，预计2026年第一季度首例患者入组。Zenas支付1亿美元现金首付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969"],"gpt_icon":0},{"id":"2593213634","title":"审批进度加快，年末多款创新药集中获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593213634","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593213634?lang=zh_cn&edition=full","pubTime":"2025-12-24 13:56","pubTimestamp":1766555761,"startTime":"0","endTime":"0","summary":"江海证券研报认为，此次“四连发”不仅是审评审批效率的体现，更标志着中国创新药研发成果迎来一轮密集的上市收获期。2024年，我国有48个创新药获批上市。此前的12月7日，国家药监局党组成员、副局长杨胜对外表示，今年以来，中国批准上市的创新药，截至当天，达到69个，已经超过了去年全年，再次创造了历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU2488822045.USD","BK1588","09688","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2593419285","title":"普华永道徐佳：中国创新药迎分水岭，量质转型呈分化格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419285?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:54","pubTimestamp":1766494448,"startTime":"0","endTime":"0","summary":"普华永道中国医药医疗行业主管合伙人徐佳博士在接受21世纪经济报道记者专访时指出，中国创新药已进入“量质转型的分水岭阶段”，呈现“头部崛起、中小突围”的分化格局，而非行业全面复苏。当前，随着2025年国家医保药品目录正式披露，支付端对创新药的支持力度","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223205718a46f0791&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1589","HK0000165453.HKD","LU2097828805.USD","LU1969619763.USD","LU2097828714.EUR","BK1583","LU2488822045.USD","LU2097828474.EUR","LU2328871848.SGD","BK1574","LU0455707207.USD","06978","LU2097828631.EUR","LU0502904849.HKD","LU2242644610.SGD","01801","01530","LU2097828557.USD"],"gpt_icon":0},{"id":"2593418537","title":"每日卖空追踪 | 诺诚健华 12月23日卖空量成交15万股，卖空比例为3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418537?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478642,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月23日，跌0.08%，卖空量成交15万股，较上一交易日减少50.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163627a6c520a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163627a6c520a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2593424149","title":"诺诚健华12月23日遭主力抛售106.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593424149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593424149?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:15","pubTimestamp":1766477706,"startTime":"0","endTime":"0","summary":"12月23日, 诺诚健华股价跌0.08%，报收13.13元，成交金额5924.0万元，换手率0.30%，振幅3.42%，量比0.62。诺诚健华今日主力资金净流出106.0万元，上一交易日主力净流出491.4万元。该股近5个交易日下跌0.68%，主力资金累计净流入313.3万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1121.8万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161519a6c50749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223161519a6c50749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2593463647","title":"医药生物行业跟踪周报：银屑病口服TYK2/IL23双雄并立格局确立 建议关注益方生物 诺诚健华 海思科等","url":"https://stock-news.laohu8.com/highlight/detail?id=2593463647","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593463647?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"2025 年12 月18 日，济民可信集团宣布，其申报的2.2 类及2.4 类新药JMX-2005 注射液已获国家药品监督管理局批准开展临床试验。随着武田新一代TYK2 抑制剂Zasocitinib 三期临床阳性顶线数据的出炉，叠加强生口服IL23 受体拮抗剂Icotrokinra 关键三期研究数据的持续兑现，银屑病口服治疗领域TYK2/IL23 双雄并立的格局正式确立。建议关注在TYK2 赛道具备差异化竞争优势的公司：如益方生物、诺诚健华等，以及布局口服IL23 相关领域的公司：如海思科等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223071133a6c31d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","03933","01276","02615","01801","BK1574","09969","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0784},{"period":"1month","weight":-0.0059},{"period":"3month","weight":-0.0836},{"period":"6month","weight":-0.1554},{"period":"1year","weight":1.5579},{"period":"ytd","weight":0.0959}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.080151},{"month":2,"riseRate":0.6,"avgChangeRate":0.148393},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}